Ignyta (RXDX) announced that the FDA has approved its IDE (investigational device exemption) for its companion diagnostic next-generation sequencing (NGS) assay, Trailblaze Pharos. The company intends to use it to identify patients with NTRK1/2/3-, ROS1- or ALK-positive solid tumors to determine eligibility in its Phase 2 STARTRK-2 clinical trial evaluating lead product candidate entrectinib in a range of cancers, particularly non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).